January 14, 2019 5:49pm
The days of being long are NOT the strongest investing rationale …
Financings: Stemline Therapeutics (STML) proposes 6.6 M share offering. J.P. Morgan Securities is acting as book-running manager for the offering. STML closed down -$0.81 at $9.07 and in the aftermarket is further negative -$0.48 or -5.29% on the news. Think $8.35 to $8.50 for pricing. Alnylam Pharmaceuticals (ALNY) proposes 5 M share offering with 750 K over-allotment. Barclays Capital is acting as sole book-running manager for the offering. ALNY closed down -$5.10 to $84.02 and in the aftermarket is further negative -$3.03 or -3.61% to $80.88 on the news. Think $80.00 for pricing. Mesoblast (MESO) digs $15 M deeper into its $75 M debt facility from Hercules Capital.
Review the daily metrics of volume, volatility, up and downside shre pricing "numbers", a short history of the IBB and the monthly "rack"!
When is it wrong to be right so often? Your portfolio should be profiting from RMi’s analysis! Every day, I “speak from my bones”; it’s time for you to step-up for continued access to what one industry CEO calls the “bible” for smart investing in the RegMed, gene and cell therapy sector.
Members only. Please login.